Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
87 0 |
SM ISO690:2012 GERVASI, Giuseppe, CAPANNA, Alessandra, MÎȚA, Valentin, ZARATTI, Laura, FRANCO, Elisabetta. Nosocomial rotavirus infection: An up to date evaluation of European studies. In: Human Vaccines and Immunotherapeutics, 2016, vol. 12, pp. 2413-2418. ISSN 2164-5515. DOI: https://doi.org/10.1080/21645515.2016.1183858 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Human Vaccines and Immunotherapeutics | ||||||
Volumul 12 / 2016 / ISSN 2164-5515 /ISSNe 2164-554X | ||||||
|
||||||
DOI:https://doi.org/10.1080/21645515.2016.1183858 | ||||||
Pag. 2413-2418 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Rotavirus (RV) is worldwide considered as the most important viral agent of acute gastroenteritis in children less than 5 y. Since 2006, the availability of anti-RV vaccines has deeply modified the incidence and economic burden of RV infection. In Europe, some countries have introduced an anti-RV vaccination program in the last 10 y. Although community acquired RV (CARV) disease is the most studied condition of RV infection, recently some authors have highlighted the importance of nosocomial RV (nRV) disease as an emerging public health issue. The aim of this review is to summarize the epidemiology of both CARV and nRV, in order to discuss the difficulty of a clear evaluation of the burden of the disease in absence of comparable data. In particular, we focused our attention to European studies regarding nRV in terms of divergences related to definition, report of incidence rate and methodological issues. |
||||||
Cuvinte-cheie acute gastroenteritis, community acquired infection, diarrhea, European, follow up, health care cost, health care organization, hospital admission, hospital discharge, hospital infection, human, length of stay, prevalence, public health, review, risk factor, rotavirus infection, Community-Acquired Infections, Cost of Illness, Cross Infection, Europe, Gastroenteritis, Rotavirus Infections |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-195577</cfResPublId> <cfResPublDate>2016-09-01</cfResPublDate> <cfStartPage>2413</cfStartPage> <cfISSN>2164-5515</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/195577</cfURI> <cfTitle cfLangCode='EN' cfTrans='o'>Nosocomial rotavirus infection: An up to date evaluation of European studies</cfTitle> <cfKeyw cfLangCode='EN' cfTrans='o'>acute gastroenteritis; community acquired infection; diarrhea; European; follow up; health care cost; health care organization; hospital admission; hospital discharge; hospital infection; human; length of stay; prevalence; public health; review; risk factor; rotavirus infection; Community-Acquired Infections; Cost of Illness; Cross Infection; Europe; Gastroenteritis; Rotavirus Infections</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Rotavirus (RV) is worldwide considered as the most important viral agent of acute gastroenteritis in children less than 5 y. Since 2006, the availability of anti-RV vaccines has deeply modified the incidence and economic burden of RV infection. In Europe, some countries have introduced an anti-RV vaccination program in the last 10 y. Although community acquired RV (CARV) disease is the most studied condition of RV infection, recently some authors have highlighted the importance of nosocomial RV (nRV) disease as an emerging public health issue. The aim of this review is to summarize the epidemiology of both CARV and nRV, in order to discuss the difficulty of a clear evaluation of the burden of the disease in absence of comparable data. In particular, we focused our attention to European studies regarding nRV in terms of divergences related to definition, report of incidence rate and methodological issues.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-115666</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-115669</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-99133</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-115668</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-115670</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfFedId> <cfFedIdId>ibn-doi-195577</cfFedIdId> <cfFedId>10.1080/21645515.2016.1183858</cfFedId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> <cfFedId_Class> <cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId> <cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId> </cfFedId_Class> <cfFedId_Srv> <cfSrvId>5123451</cfSrvId> <cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId> </cfFedId_Srv> </cfFedId> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-115666</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-115666-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> <cfFamilyNames>Gervasi</cfFamilyNames> <cfFirstNames>Giuseppe</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-115669</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-115669-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> <cfFamilyNames>Capanna</cfFamilyNames> <cfFirstNames>Alessandra</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-99133</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-99133-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> <cfFamilyNames>Mîța</cfFamilyNames> <cfFirstNames>Valentin</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-115668</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-115668-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> <cfFamilyNames>Zaratti</cfFamilyNames> <cfFirstNames>Laura</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-115670</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-115670-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-09-01T24:00:00</cfStartDate> <cfFamilyNames>Franco</cfFamilyNames> <cfFirstNames>Elisabetta</cfFirstNames> </cfPersName_Pers> </cfPers> <cfSrv> <cfSrvId>5123451</cfSrvId> <cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName> <cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr> <cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw> </cfSrv> </CERIF>